Get the Stockscreener App
124.34
2.09%
-2.59
Incyte Corp stock is traded at $124.34, with a volume of 586.83K.
It is down -2.09% in the last 24 hours and down -2.76% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$126.93
Open:
$127.51
24h Volume:
586.83K
Relative Volume:
0.36
Market Cap:
$25.18B
Revenue:
$5.36B
Net Income/Loss:
$1.43B
P/E Ratio:
17.58
EPS:
7.0718
Net Cash Flow:
$1.42B
1W Performance:
-0.38%
1M Performance:
-2.76%
6M Performance:
+37.40%
1Y Performance:
+47.01%
1-Day Range:
$123.89
$128.21
1-Week Range:
$123.89
$128.72
52-Week Range:
$81.09
$132.60
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
124.20 | 25.73B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
511.76 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
792.40 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
184.21 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
940.82 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
362.57 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - marketwatch.com
Incyte Corporation (INCY) latest stock news and headlines - Yahoo Finance UK
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says - marketscreener.com
INCY Reiterated by RBC Capital -- Price Target Maintained at $10 - GuruFocus
Incyte to present inflammation and autoimmunity data at EADV - Investing.com
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio - Business Wire
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
INCY Looks 18.6% Overvalued on GF Value™ as of September 2026 - GuruFocus
Incyte Expands Skin Diseases Treatment Partnership in Australia - marketscreener.com
Incyte stock heads into the open after a 1.8% pullback - AD HOC NEWS
Specialised Therapeutics expands Incyte partnership to Australia - Investing.com
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte stock gains institutional backing as Bank of America boosts position - AD HOC NEWS
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Yahoo Finance
What Is Incyte Corporation (NASDAQ:INCY) Signaling Through Its Pipeline? - Kalkine Media
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
Incyte stock gains as investors eye September FDA decision and pipeline catalysts - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum - ChartMill
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains? - Stocktwits
Incyte stock heads into the open after a 2.5% gain - AD HOC NEWS
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains - marketwatch.com
Incyte Insider Sold Shares Worth $2,797,629, According to a Recent SEC Filing - marketscreener.com
Incyte (INCY) R&D chief exercises options and sells 23,218 shares - Stock Titan
Incyte Corp. (INCY) Gains 1.85% to $123.99, Holding Near the Midpoint of Its Recent RangeLow Vol ETF - careplusvn.com
Incyte: Priced For Success, With No Margin Of Safety (NASDAQ:INCY) - Seeking Alpha
Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com
Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce - GuruFocus
Incyte agrees CMS pricing deal for Jakafi, avoids certain future mandates; no change to 2026 guidance - TradingView
Incyte (NASDAQ: INCY) expects to sidestep new CMS drug pricing rules - Stock Titan
Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services - marketscreener.com
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks - Yahoo Finance
Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734 - Yahoo Finance
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Incyte Corp Stock (INCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | President, Global Head of R&D |
Sep 15 '26 |
Sale |
120.49 |
23,218 |
2,797,629 |
183,200 |
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):